Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  The Journal of Heart and Lung Transplantation

• Publication date

  2006-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.HEALUN.2006.02.010PMID 16730571
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation

  2006cited by this paper
• Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update.

  2006cited by this paper
• Colloids decrease clot propagation and strength: role of factor XIII‐fibrin polymer and thrombin–fibrinogen interactions

  2005cited by this paper
• Effects of PentaLyte® and Voluven® hemodilution on plasma coagulation kinetics in the rabbit: role of thrombin‐fibrinogen and factor XIII‐fibrin polymer interactions

  2005cited by this paper
• Successful Use of Recombinant Hirudin and Its Monitoring by Ecarin Clotting Time in Patients with Heparin‐Induced Thrombocytopenia Undergoing Off‐Pump Coronary Artery Revascularization

  2005cited by this paper
• Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia.

  2005cited by this paper
• Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia.

  2005cited by this paper
• Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography

  2005cited by this paper
• The Effect of Dilution on Plasma Coagulation Kinetics Determined by Thrombelastography Is Dependent on Antithrombin Activity and Mode of Activation

  2004cited by this paper
• Bivalent direct thrombin inhibitors: hirudin and bivalirudin.

  2004cited by this paper
• A Novel Thrombelastograph® Tissue Factor/Kaolin Assay of Activated Clotting Times for Monitoring Heparin Anticoagulation During Cardiopulmonary Bypass

  2004cited by this paper
• Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost.

  2004cited by this paper
• The Impact of Factor XIII on Coagulation Kinetics and Clot Strength Determined by Thrombelastography

  2004cited by this paper
• Benefit-Risk Assessment of Treatments for Heparin-Induced Thrombocytopenia

  2003cited by this paper
• Heparin-induced thrombocytopenia.

  2003cited by this paper
• Heparin‐induced thrombocytopenia

  2003cited by this paper
• The Plasma Supplemented Modified Activated Clotting Time for Monitoring of Heparinization During Cardiopulmonary Bypass: A Pilot Investigation

  2002cited by this paper
• Heparin-induced thrombocytopenia: a common complication in cardiac transplant recipients.

  2002cited by this paper
• Heparin-induced thrombocytopenia

  2001cited by this paper
• Anticoagulation during Cardiopulmonary Bypass in Patients with Heparin-induced Thrombocytopenia Type II and Renal Impairment Using Heparin and the Platelet Glycoprotein IIb–IIIa Antagonist Tirofiban

  2001cited by this paper
• The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations.

  2001cited by this paper
• Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia.

  2001cited by this paper
• Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant.

  2000cited by this paper
• Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia

  2000cited by this paper
• Management strategies for heparin-induced thrombocytopenia in heart-transplant candidates: case report and review of the literature.

  2000cited by this paper
• Protamine Reversal of Heparin Affects Platelet Aggregation and Activated Clotting Time After Cardiopulmonary Bypass

  1998cited by this paper
• Heparin-induced thrombocytopenia.

  1996cited by this paper
• Plasmapheresis. A therapeutic option in the management of heparin-associated thrombocytopenia with thrombosis.

  1991cited by this paper
• Heparin-associated thrombocytopenia: alternative managements.

  1986cited by this paper
• Heparin-associated thrombocytopenia.

  1984cited by this paper

• Dabigatran-idarucizumab pharmacokinetics-pharmacodynamics in sheep undergoing cardiopulmonary bypass.

  2025cites this paper
• Correlation between heparin anti‐Xa activity and thromboelastography in adult critically ill COVID‐19 patients

  2023cites this paper
• Intravenous Dabigatran Provides Adequate Anticoagulation for Cardiopulmonary Bypass Using a Rabbit Model

  2023cites this paper
• Correlation between partial thromboplastin time and thromboelastography in adult critically ill patients requiring bivalirudin for extracorporeal membrane oxygenation

  2023cites this paper
• Searching for an Alternate Anticoagulant for Cardiopulmonary Bypass: Does Two Plus Two Equal Two?

  2022cites this paper
• Alternatives to heparin anticoagulation for cardiopulmonary bypass and extracorporeal membrane oxygenation

  2021cites this paper
• High-Dose Dabigatran Is an Effective Anticoagulant for Simulated Cardiopulmonary Bypass Using Human Blood.

  2020cites this paper
• Point-of-Care Hematology

  2020cites this paper
• Comparison of the antiplatelet and antithrombotic effects of bivalirudin versus unfractionated heparin: A platelet substudy of the HEAT PPCI trial.

  2018cites this paper
• Rotational Thromboelastometry for Coagulation Management During Cardiopulmonary Bypass Using Argatroban.

  2018cites this paper
• Optical sensing of anticoagulation status: Towards point-of-care coagulation testing

  2017cites this paper
• Point-of-care coagulation management algorithms during ECMO support: are we there yet?

  2016cites this paper
• Thrombosis in Continuous‐Flow Left Ventricular Assist Devices: Pathophysiology, Prevention, and Pharmacologic Management

  2015cites this paper
• Quantification of Fibrinolysis Using Velocity Curves Measured with Thromboelastometry in Children with Congenital Heart Disease

  2015cites this paper
• Use of viscoelastic haemostatic assay in emergency and elective surgery.

  2014cites this paper
• Systematic evaluation of evidence on veterinary viscoelastic testing part 4: Definitions and data reporting.

  2014cites this paper
• Partnership on Rotational ViscoElastic Test Standardization (PROVETS): evidence-based guidelines on rotational viscoelastic assays in veterinary medicine.

  2014cites this paper
• Thrombosis during off pump LVAD placement in a patient with heparin induced thrombocytopenia using bivalirudin

  2013cites this paper
• Point of care devices for assessing bleeding and coagulation in the trauma patient.

  2013cites this paper
• Bivalirudin is inferior to heparin in preservation of intraoperative autologous blood.

  2012cites this paper
• Bivalirudin

  2012cites this paper
• Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass

  2012cites this paper
• Pharmacotherapy for Mechanical Circulatory Support: A Comprehensive Review

  2011cites this paper
• Lepirudin dose-dependently increases thrombelastography parameters at therapeutic plasma concentrations as measured with ROTEM® - a pilot study.

  2011cites this paper
• Comparative hemostasis: animal models and new hemostasis tests.

  2011cites this paper
• An evaluation of monitoring possibilities of argatroban using rotational thromboelastometry and activated partial thromboplastin time

  2010cites this paper
• Antithrombotic therapy for the CardioWest temporary total artificial heart.

  2010cites this paper
• Case report: a thrombus in the venous reservoir while using bivalirudin in a patient with heparin-induced thrombocytopenia undergoing heart transplantation.

  2010cites this paper
• M-AAA-thrombin: potent anticoagulant and antiplatelet thrombin derivative with differential affinity for factor VIII and PAR1.

  2010cites this paper
• Plasmapheresis and Heparin Reexposure as a Management Strategy for Cardiac Surgical Patients with Heparin-Induced Thrombocytopenia

  2010cites this paper
• A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation.

  2009cites this paper
• Argatroban

  2009cites this paper
• Reducing Harm Associated with Anticoagulation

  2009cites this paper
• Reducing Harm Associated with Anticoagulation Considerations of Argatroban Therapy in

  2009cites this paper
• Direct thrombin inhibitors in patients with mechanical heart valves: Ready for clinical trials?

  2009cites this paper
• Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cites this paper
• Efficacy of intravenous iron sucrose administration for correcting preoperative anemia in patients scheduled for major orthopedic surgery.

  2008cites this paper
• Argatroban therapy in heparin-induced thrombocytopenia

  2008cites this paper
• Thrombelastography in a patient with heparin-induced thrombocytopenia treated with argatroban.

  2008cites this paper
• Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction

  2008cites this paper
• Beneficial effects of statin therapy on infection related mortality in patients with atherosclerotic and cardiovascular disease.

  2008cites this paper
• Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin.

  2008cites this paper
• Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII

  2008cites this paper
• Coagulation Monitoring: Current Techniques and Clinical Use of Viscoelastic Point-of-Care Coagulation Devices

  2008cites this paper
• (8th Edition) Evidence-Based Clinical Practice Guidelines American College of Chest Physicians Heparin-Induced Thrombocytopenia: Treatment and Prevention of

  2008cites this paper
• Efficacy of Intravenous Iron Sucrose Administration for Correcting Preoperative Anemia in Patients Scheduled for Major Orthopedic Surgery

  2008cites this paper
• Hydroxyethyl starch enhances argatroban-mediated decreases in clot propagation and strength by diminishing thrombin–fibrinogen interactions

  2007cites this paper
• Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia

  2007cites this paper
• Thrombin Generation Assay and Viscoelastic Coagulation Monitors Demonstrate Differences in the Mode of Thrombin Inhibition Between Unfractionated Heparin and Bivalirudin

  2007cites this paper
• Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation

  2007cites this paper
• Direct Antithrombins

  2007cites this paper
• Thrombelastographic method to quantify the contribution of factor XIII to coagulation kinetics

  2007cites this paper
• Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors

  2007cites this paper
• Thrombelastographic measures of clot propagation: a comparison of alpha with the maximum rate of thrombus generation

  2007cites this paper
• Qualitative Thrombelastographic Detection of Tissue Factor in Human Plasma

  2007influential citation